Polygenic risk score may identify more clinically significant PCa than PSA, MRI
April 10th 2025"Building on decades of research into the genetic markers of prostate cancer, our study shows that the theory does work in practice—we can identify men at risk of aggressive cancers who need further tests and spare the men who are at lower risk from unnecessary treatments," says professor Ros Eeles.
Label change for testosterone: Implications for urologists, prescribers, and patients
April 9th 2025In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.
Genetic test can predict risk of toxicity following radiation for prostate cancer
April 7th 2025"This finding reinforces PROSTOX ultra as a true measure of the biological response to radiation, independent of treatment era or technique that can identify the safest course of treatment to avoid toxicity," says Amar U. Kishan, MD.
Naeem Bhojani, MD, discusses WATER III data on Aquablation vs enucleation for BPH
April 6th 2025"This study was an investigator initiated study, and what they wanted to do was a randomized trial for large prostates, so 80 to 180 grams, between Aquablation and prostate enucleation," says Naeem Bhojani, MD, FRCSC.
UroLift may offer improved early recovery period vs Rezūm for BPH
April 4th 2025“The differences in patient experience between UroLift System and Rezūm, particularly in terms of early recovery, sexual function, and overall satisfaction, are key considerations for both clinicians and patients selecting a treatment path," says Mark Rochester, MD, FRCS.
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
April 3rd 2025"We see the overall survival, whether it is [in] all-comers, in HRR gene mutation-positive patients, or in HRR gene [mutation]-negative patients or [those] who did not have mutations, the overall survival is about 45 to 47 months," says Neeraj Agarwal, MD, FACS.
Eugene Cone, MD, outlines potential impact of Expanded Access Program for rBCG
April 1st 2025“If it is as efficacious as it looks, we will have more patients who are getting effective standard of care treatment, not needing to go on to further treatment, not having recurrences, [having decreased] morbidity from repeated resections, and saving bladders in the process," says Eugene B. Cone, MD.